Welcome to our dedicated page for Outlook Therapeutics SEC filings (Ticker: OTLK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Outlook Therapeutics, Inc. filings document material events for a Nasdaq-listed biopharmaceutical company focused on ONS-5010/LYTENAVA for wet AMD and other retina-disease applications. The company’s 8-K disclosures cover FDA-related communications for its biologics license application, including Complete Response Letter follow-up, Type A meeting activity and formal dispute-resolution matters.
Regulatory filings also describe capital-structure activity involving common stock, warrants, registered and unregistered securities, note financing and amendments to debt instruments. Governance records include shareholder voting results, board composition changes, proxy-related matters, Nasdaq-listed common stock information, exhibits and risk-factor or material-agreement disclosures tied to financing and regulatory developments.
Outlook Therapeutics, Inc. received U.S. FDA approval for LYTENAVA™ (bevacizumab-vikg), an ophthalmic formulation of bevacizumab, for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). LYTENAVA is described as the first and only FDA-approved ophthalmic bevacizumab for wet AMD in the United States.
The company anticipates that this approval will provide 12 years of Reference Product Exclusivity under the BPCIA. It highlights the U.S. anti-VEGF retina market as approximately $8.5 billion annually and is executing a commercial launch aimed at broad reimbursement, physician support, and patient access, with availability for eligible U.S. patients expected before year-end.
LYTENAVA already holds centralized Marketing Authorization in the EU and authorization in the UK for wet AMD, with commercial launches commenced in Germany, Austria, and the UK. Safety information notes risks typical of intravitreal VEGF inhibitors, including endophthalmitis, retinal detachment, intraocular pressure increases, and a potential risk of arterial thromboembolic events, with common adverse reactions including conjunctival hemorrhage (4%), eye pain (2%), and vitreous floaters (2%).
Outlook Therapeutics, Inc. approved new equity and cash incentives for its chief executive and chief financial officers tied to potential FDA approval of ONS-5010 (bevacizumab-vikg). The awards recognize their efforts during 2025 and 2026 advancing the Biologics License Application through FDA review and appeal processes.
The chief executive officer received options to purchase 100,000 shares and the chief financial officer 210,078 shares under the 2024 Equity Incentive Plan, all at an exercise price of $1.4304 per share, vesting on July 21, 2027 subject to continued service. They also received cash bonus opportunities of $420,000 and $200,000, respectively, which will be earned and payable only if, on or before July 31, 2026, the FDA approves ONS-5010 and issues a favorable decision on the Biologics License Application and each executive remains in service through payment.
Outlook Therapeutics, Inc. reported that Chief Financial Officer Lawrence A. Kenyon received a grant of 210,078 stock options on July 21, 2026 under its 2024 Equity Incentive Plan. Each option covers one share of common stock at an exercise price of 1.4304 per share, vests in full on July 21, 2027, and expires on July 21, 2036, conditional on his continued service.
Outlook Therapeutics, Inc. reports that Chief Executive Officer Robert Charles Jahr received a grant of stock options covering 100,000 shares of common stock at an exercise price of $1.4304 per share. Granted on July 21, 2026 under the 2024 Equity Incentive Plan, the options vest in full on July 21, 2027 and expire on July 21, 2036, leaving him with 100,000 options held directly.
Outlook Therapeutics, Inc. is registering for resale up to 17,258,065 shares of common stock on behalf of selling stockholders. These shares consist of 16,129,033 shares issuable upon exercise of Common Warrants and 1,129,032 shares issuable upon exercise of Placement Agent Warrants from an April 23, 2026 financing. The company is not selling shares in this offering and will not receive proceeds from selling stockholders’ resales, but will receive cash only if the warrants are exercised, at $0.31 per Common Warrant share and $0.3875 per Placement Agent Warrant share.
Outlook Therapeutics is a biopharmaceutical company focused on ONS-5010/LYTENAVA, the first authorized ophthalmic bevacizumab for wet AMD in the EU and UK, with launches begun in Germany and the UK and additional EU launches planned. In the U.S., the FDA initially issued multiple Complete Response Letters but, after a Formal Dispute Resolution process, concluded substantial evidence of effectiveness has been established, and the company resubmitted its BLA in June 2026. The anti-VEGF retina market is described as approximately $3.6 billion in Europe, $8.5 billion in the U.S., and $16 billion globally. KPMG’s audit report includes a going-concern explanatory paragraph citing recurring losses, negative cash flows and an accumulated deficit.
Outlook Therapeutics, Inc. has filed a Form S-3 for the resale of up to 17,258,065 shares of common stock by existing holders. These shares are issuable upon exercise of warrants issued in an April 23, 2026 financing, including 16,129,033 investor warrants and 1,129,032 placement agent warrants.
The company will not receive proceeds from resale of the shares, but would receive cash if the warrants are exercised at $0.31 and $0.3875 per share, respectively. Common warrants are exercisable starting July 16, 2026 and generally expire in 2031, subject to 4.99% or 9.99% beneficial ownership limits. As of June 22, 2026, 186,996,998 shares were outstanding.
Outlook describes its lead product ONS-5010/LYTENAVA, an ophthalmic bevacizumab approved in the EU and UK for wet AMD, and details a multi-year regulatory path with the FDA culminating in a June 2026 BLA resubmission after a successful appeal that led FDA to conclude substantial evidence of effectiveness. The auditor’s report for fiscal 2025 includes a going concern paragraph citing recurring losses and negative operating cash flows.
Outlook Therapeutics, Inc. held a special meeting of stockholders on July 16, 2026. Stockholders approved the potential issuance of common shares underlying warrants issued in connection with an April 2026 registered direct offering, including up to 16,129,033 shares from Private Placement Warrants and up to 2,258,064 shares from Placement Agent Warrants, as well as 2,142,854 shares underlying amended previously issued warrants.
Stockholders also approved amending the Restated Certificate of Incorporation to increase authorized common stock from 260,000,000 to 600,000,000 shares. In addition, they approved an amendment authorizing the board to implement a reverse stock split, with a corresponding proportional reduction in authorized shares, at a ratio between 1-for-10 and 1-for-50.
For the meeting, 62,303,960 shares, representing approximately 51.5% of the 120,863,252 shares outstanding as of the record date, were present or represented by proxy.
Outlook Therapeutics, Inc. reports that it has regained compliance with Nasdaq’s minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company received notice that its common stock closed at or above $1.00 per share for ten consecutive business days between June 11, 2026 and June 25, 2026, satisfying Nasdaq Listing Rule 5550(a)(2). This closes a prior delisting determination that had been triggered when the stock traded below $1.00 for 30 consecutive business days.
Outlook Therapeutics reported that the U.S. FDA has acknowledged receipt of its resubmitted Biologics License Application (BLA) for ONS-5010/LYTENAVA (bevacizumab-vikg) as a treatment for wet age-related macular degeneration. The FDA classified the resubmission as a Class 1 review, triggering a 60-day review period and setting a Prescription Drug User Fee Act (PDUFA) target action date of July 29, 2026.
The company describes ONS-5010/LYTENAVA as an ophthalmic formulation of bevacizumab that is already covered by centralized Marketing Authorization in the EU and authorization by the UK MHRA for wet AMD, with commercial launch commenced in Germany, Austria, and the UK. In the United States, the product remains investigational and subject to the outcome of this BLA review.